Peer Exchange

Overview of Uncontrolled Asthmatic Episode

Quality of Life and Increased Risk of Asthma Exacerbations

Pathogenesis of Plaque Psoriasis and Triggering Factors

Clinical Manifestations and Progressive Nature of Psoriasis

Factors That Influence Choice of Treatment for Plaque Psoriasis

Effect of Multiple Sclerosis and Obesity on Treatment of Psoriasis

Medical Benefit of Office Administration of Tildrakizumab

Experience With Using Older Biologics to Treat Psoriasis

Adverse Events of TNF Inhibitors Used to Treat Psoriasis

Contraindications to the Conventional Treatment for Psoriasis

HIV as a Contraindication for Treatment of Psoriasis

Managing Depression as a Psychological Effect of Psoriasis

IL-23 Inhibitors for Treatment of Plaque Psoriasis

Case Study of a 23-Year-Old Female With Plaque Psoriasis

49-Year-Old Female With Psoriasis and Latent Tuberculosis

Elderly Male With Plaque Psoriasis, Metabolic Syndrome

Challenges in Treating Patients With Plaque Psoriasis

Unmet Needs and Emerging Treatments for Psoriasis

Guidelines to Manage Blood Cholesterol

Targeting LDL Cholesterol

Coronary Calcium Scoring to Assess Cardiovascular Risk

Disparities in Lipid Management

Statin Therapy Selection and Shared Decision-Making

Management of Statin Intolerance/Myalgias

Overview of Cardiovascular Risks

Prevalence of CVD Associated With Hypercholesterolemia

CVD Risk Reduction and Prevention

CVD: REDUCE-IT Trial

CVD: EVAPORATE Trial and COVID-19 Pilot Study

Add-On Therapy With Statins and PCSK9 Inhibitors in CVD

Adverse Effects of PCSK9 Inhibitors in CVD

CVD Real-World Case Scenario 1

CVD Real-World Case Scenario 2

CVD Real-World Case Scenario 3

Treatment of CVD: Bempedoic Acid Monotherapy + Ezetimibe

Emerging Therapies for the Treatment of CVD

Closing Thoughts for the Management of CVD

Psoriatic Arthritis Patient Case Overview and Therapeutic Goals

Atopic Dermatitis: Age of Onset and Prevalence

Impact of Atopic Dermatitis: Pediatrics Versus Adults

Presentation and Severity of Atopic Dermatitis

Seeking Care for Atopic Dermatitis

Nonpharmacological Approach to Managing Atopic Dermatitis

Pediatric AD: State-of-the-Art Treatment

Moderate to Severe Disease: Systemic Therapy

Monoclonal Antibody Therapy for Pediatrics With AD

Monoclonal Antibody Prior Authorization

Topical Therapy Approach for Pediatric Atopic Dermatitis

First-Line Biologics for Pediatric AD and Psoriasis

The Shifting Treatment Paradigm in AD Management

Atopic Dermatitis Pathophysiology

Pediatric AD: Differential Diagnosis and Tools

Monoclonal Antibody FDA Approval for Pediatric Population

Monoclonal Antibody Toxicity Profile and Patient Impact

Developing Treatments for Pediatric Atopic Dermatitis